Cyr61 is abnormally expressed in tumors, and dysregulated Cyr61 promotes tumor proliferation and mediates drug resistance in tumor cells (Zhu et al. 2016; Xie et al. 2001, 2004; Lin et al. 2005; Gery et al. 2005). Here, CCN1 is linked to neoplasm.